Ivy Lane Capital Management’s Quest Diagnostics DGX Stock Holding History

Ivy Lane Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.68M	Hold	29,000	–	–	8.59%	5
2025 Q4	$5.03M	Hold	29,000	–	–	6.36%	5
2025 Q3	$5.53M	Sell	29,000 -21,000	-42%	-$3.73M	6.18%	7
2025 Q2	$8.98M	Sell	50,000 -7,000	-12%	-$1.22M	4.95%	7
2025 Q1	$9.64M	Hold	57,000	–	–	5.81%	6
2024 Q4	$8.6M	Hold	57,000	–	–	4.64%	10
2024 Q3	$8.85M	Buy	57,000 +10,000	+21%	+$1.49M	5%	8
2024 Q2	$6.43M	Buy	47,000 +7,000	+18%	+$959K	3.74%	9
2024 Q1	$5.32M	Buy	+40,000	New	+$5.19M	3.26%	11

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Ivy Lane Capital Management's DGX Position: Q1 2026 in Review

Ivy Lane Capital Management held its Quest Diagnostics (DGX) position steady in Q1 2026 at 29,000 shares worth $5.68M. The position accounts for 8.59% of the portfolio, ranked #5.

Ivy Lane Capital Management first reported a position in DGX in Q1 2024 and has held it in 9 quarters since. The position peaked at $9.64M in Q1 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

Ivy Lane Capital Management held 29,000 shares of Quest Diagnostics worth $5.68M as of Q1 2026.
Ivy Lane Capital Management left its Quest Diagnostics share count unchanged in Q1 2026.
Quest Diagnostics made up 8.59% of Ivy Lane Capital Management's portfolio in Q1 2026, its #5 holding.
Ivy Lane Capital Management first reported a position in Quest Diagnostics in Q1 2024 and has held it in 9 quarters since.
Ivy Lane Capital Management's Quest Diagnostics position peaked at $9.64M in Q1 2025.
1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Ivy Lane Capital Management's 13F filing for Q1 2026, filed 12 May 2026.